Core Viewpoint - BeiGene (ONC.US) experienced a significant increase of over 9%, closing at $334.20, following the release of its financial report for the first half of 2025, which showed a total revenue of 17.518 billion yuan, a year-on-year growth of 46.03% [1] Financial Performance - The total revenue for the first half of 2025 reached 17.518 billion yuan, with product revenue accounting for 17.36 billion yuan, reflecting a year-on-year increase of 45.8% [1] - The company achieved a net profit of 450 million yuan, marking its first profitable quarter of the year [1] Product Performance - The growth in product revenue was driven by sales increases of self-developed products, namely Brukinsa (Zebutinib capsules) and Tislelizumab (anti-PD-1 monoclonal antibody), as well as increased sales from Amgen licensed products [1] - Brukinsa demonstrated outstanding performance, becoming the leading BTK inhibitor in both the U.S. and global markets [1] Sales Breakdown - Global sales of Brukinsa reached 12.527 billion yuan, representing a year-on-year growth of 56.2% [1] - In the U.S. market, sales of Brukinsa amounted to 8.958 billion yuan, with a year-on-year increase of 51.7% [1] - Brukinsa has rapidly gained adoption among patients and physicians in the U.S. due to its best-in-class clinical characteristics, making it the largest and fastest-growing product in the market [1]

Core Viewpoint - BeiGene (ONC.US) experienced a significant increase of over 9%, closing at $334.20, following the release of its financial report for the first half of 2025, which showed a total revenue of 17.518 billion yuan, a year-on-year growth of 46.03% [1] Financial Performance - The company reported total revenue of 17.518 billion yuan for the first half of 2025, marking a 46.03% increase year-on-year [1] - Product revenue reached 17.36 billion yuan, reflecting a year-on-year growth of 45.8% [1] - The net profit for the company was 450 million yuan, marking its first return to profitability this year [1] Product Performance - The growth in product revenue was driven by sales increases of self-developed products, namely Brukinsa (Zebutinib) and Tazverik (Tazemetostat), as well as increased sales from Amgen licensed products [1] - Zebutinib demonstrated outstanding performance, becoming the leading BTK inhibitor in both the U.S. and global markets [1] Sales Data - Global sales of Zebutinib reached 12.527 billion yuan, representing a year-on-year growth of 56.2% [1] - In the U.S. market, Zebutinib sales amounted to 8.958 billion yuan, with a year-on-year increase of 51.7% [1] - Zebutinib has rapidly gained adoption among patients and physicians in the U.S. due to its best-in-class clinical characteristics, making it the largest and fastest-growing product in the market [1]

Core Viewpoint - BeiGene (ONC.US) experienced a significant increase of over 9%, closing at $334.20, following the release of its financial report indicating a strong revenue growth and a return to profitability in the first half of 2025 [1] Financial Performance - In the first half of 2025, the company achieved total revenue of 17.518 billion yuan, representing a year-on-year growth of 46.03% [1] - Product revenue reached 17.36 billion yuan, with a year-on-year increase of 45.8% [1] - The company reported a net profit of 450 million yuan, marking its first return to profitability this year [1] Product Performance - The growth in product revenue was driven by sales increases of self-developed products, namely Brukinsa® (Zebutinib capsules) and Tislelizumab, as well as increased sales from Amgen licensed products [1] - Zebutinib demonstrated outstanding performance, becoming the leading BTK inhibitor in both the U.S. and global markets [1] Sales Data - Global sales of Zebutinib reached 12.527 billion yuan, reflecting a year-on-year growth of 56.2% [1] - In the U.S. market, sales of Zebutinib amounted to 8.958 billion yuan, with a year-on-year increase of 51.7% [1] - Zebutinib has rapidly gained adoption among patients and physicians in the U.S. due to its best-in-class clinical characteristics, making it the largest and fastest-growing product in the market [1]

（文章来源：证券日报） 证券日报网讯 9月2日晚间，百济神州发布公告称，公司股票于2025年8月28日、2025年8月29日和2025 年9月1日连续三个交易日内日收盘价格涨幅偏离值累计超过30%，属于股票交易异常波动情形。经自 查，公司不存在应披露而未披露的重大事项，目前生产经营正常，未发生重大变化。公司股价短期波动 幅度较大，敬请投资者注意投资风险。 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has exceeded performance expectations in the first half of 2025, leading to an upward revision of the full-year performance guidance [8] - The revenue for the first half of 2025 reached USD 2.43 billion, a year-on-year increase of 42%, driven by the strong sales of core product Zebutini in the US and continued growth in Europe [8] - The company is expected to maintain steady revenue growth over the next three years, with significant profit release anticipated in the coming years [8] Financial Forecasts - Total revenue projections are as follows: - 2023: CNY 17,423 million - 2024: CNY 27,214 million (YoY +56.19%) - 2025: CNY 36,720 million (YoY +34.93%) - 2026: CNY 44,798 million (YoY +22.00%) - 2027: CNY 55,998 million (YoY +25.00%) [1][9] - The net profit attributable to the parent company is forecasted to improve significantly: - 2023: CNY -6,715.86 million - 2024: CNY -4,978.29 million - 2025: CNY 812.75 million (YoY +116.33%) - 2026: CNY 4,168.46 million (YoY +412.88%) - 2027: CNY 9,542.78 million (YoY +128.93%) [1][9] - The latest diluted EPS projections are: - 2023: CNY -4.70 - 2024: CNY -3.48 - 2025: CNY 0.57 - 2026: CNY 2.91 - 2027: CNY 6.67 [1][9] Key Catalysts - Important catalysts include the upcoming data readout for Sonrotoclax (BCL2 inhibitor) in late 2025 and the initiation of head-to-head trials against rival therapies [8] - The company is also advancing its pipeline in solid tumors and inflammation/immunology, with several clinical trials expected to start in 2026 [8]

智通财经APP讯，百济神州(06160)发布公告，该公司A股股票交易于连续三个交易日内(2025年8月28 日、2025年8月29日和2025年9月1日)日收盘价格涨幅偏离值累计超过30%，根据《上海证券交易所交易 规则》《上海证券交易所科创板股票异常交易实时监控细则》的有关规定，属于股票交易异常波动情 形。 公司股价短期波动幅度较大，敬请广大投资者注意投资风险，理性决策，审慎投资。 经公司自查，截至本公告披露日，公司不存在应披露而未披露的重大事项。公司目前生产经营正常，未 发生重大变化。 ...

【百济神州：公司的药物产品需完成药物早期发现等多个环节 容易受到一些不确定性因素的影响】#百 济神州发布股票交易异常波动公告#称，由于生物医药行业具有研发周期长、投入大、风险高的特点， 公司的药物产品需完成药物早期发现、临床前研究、临床开发、监管审查、生产、商业化推广等多个环 节，容易受到一些不确定性因素的影响，包括但不限于公司证明其候选药物功效和安全性的能力、候选 药物的临床结果、药监部门审查流程对临床试验的启动、时间表和进展的影响、药物或新适应症上市许 可申请技术审评及审批的进展、公司上市药物及候选药物（如能获批）获得商业成功的能力、公司获得 和维护其药物和技术的知识产权的能力、公司依赖第三方进行药物开发、生产、商业化和其他服务的情 况、公司取得监管审批和商业化药品的有限经验以及公司获得进一步的营运资金以完成候选药物开发和 实现并保持盈利的能力等。因此，公司业务运营、财务状况和经营业绩可能会受到上述不确定因素以及 其他目前未能预测的因素的影响。公司未来的业务计划、实际业绩表现、财务状况或经营结果可能与公 司预期情况有重大差异。(智通财经) ...

公司股价短期波动幅度较大，敬请广大投资者注意投资风险，理性决策，审慎投资。 经公司自查，截至本公告披露日，公司不存在应披露而未披露的重大事项。公司目前生产经营正常，未 发生重大变化。 百济神州(06160)发布公告，该公司A股股票交易于连续三个交易日内(2025年8月28日、2025年8月29日 和2025年9月1日)日收盘价格涨幅偏离值累计超过30%，根据《上海证券交易所交易规则》《上海证券 交易所科创板股票异常交易实时监控细则》的有关规定，属于股票交易异常波动情形。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 海外監管公告 本公告乃百濟神州有限公司（BeOne Medicines Ltd., 「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊發的《百濟神州有限公司股票交易異常波 動的公告》，僅供參閱。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2025年9月2日 於本公告日期，本公司董事會包括主席兼執行董事歐雷強先生、非執行董事王 曉東博士，以及獨立非執行董事Olivier Brandicourt博士、Margaret Han Dugan 博士、Michael Goller先生、Anthony C. Hooper先生、Ranjeev Krishana先生、 Alessandro Riva博士、Corazon (Corsee) ...

智通财经APP讯，百济神州(688235.SH)发布股价异动公告，由于生物医药行业具有研发周期长、投入 大、风险高的特点，公司的药物产品需完成药物早期发现、临床前研究、临床开发、监管审查、生产、 商业化推广等多个环节，容易受到一些不确定性因素的影响，包括但不限于公司证明其候选药物功效和 安全性的能力、候选药物的临床结果、药监部门审查流程对临床试验的启动、时间表和进展的影响、药 物或新适应症上市许可申请技术审评及审批的进展、公司上市药物及候选药物(如能获批)获得商业成功 的能力、公司获得和维护其药物和技术的知识产权的能力、公司依赖第三方进行药物开发、生产、商业 化和其他服务的情况、公司取得监管审批和商业化药品的有限经验以及公司获得进一步的营运资金以完 成候选药物开发和实现并保持盈利的能力等。因此，公司业务运营、财务状况和经营业绩可能会受到上 述不确定因素以及其他目前未能预测的因素的影响。公司未来的业务计划、实际业绩表现、财务状况或 经营结果可能与公司预期情况有重大差异。 ...